Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Reem Rafik AlOlaby"'
Autor:
Reem Rafik Alolaby, Poonnada Jiraanont, Blythe Durbin-Johnson, Mittal Jasoliya, Hiu-Tung Tang, Randi Hagerman, Flora Tassone
Publikováno v:
Frontiers in Genetics, Vol 11 (2020)
Sertraline is one among several selective serotonin reuptake inhibitors (SSRIs) that exhibited improvement of language development in Autism Spectrum Disorder (ASD); however, the molecular mechanism has not been elucidated. A double blind, randomized
Externí odkaz:
https://doaj.org/article/e0f4f2c4fbac4930b16a720edd04e0fa
Autor:
Hiu Tung Tang, Poonnada Jiraanont, Flora Tassone, David R Hessl, Glenda M. Espinal, Andrea Schneider, Stefan R. Sweha, Nuanchan Chutabhakdikul, Reem Rafik AlOlaby, Susan M. Rivera, Paul J. Hagerman, Marisol Silva, Blythe Durbin-Johnson, Randi J Hagerman
Publikováno v:
eNeurologicalSci, Vol 7, Iss C, Pp 49-56 (2017)
eNeurologicalSci
eNeurologicalSci
The prevalence of the fragile X premutation (55-200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes. In this study we invest
Autor:
Randi J Hagerman, Marisol Silva, Blythe Durbin-Johnson, Dalyir I. Pretto, Carolyn M. Yrigollen, Reem Rafik AlOlaby, Stefan R. Sweha, Flora Tassone
Publikováno v:
Brain & development, vol 39, iss 6
ObjectivesSeveral neurotransmitters involved in brain development are altered in fragile X syndrome (FXS), the most common monogenic cause of autism spectrum disorder (ASD). Serotonin plays a vital role in synaptogenesis and postnatal brain developme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e86644b2a71c08fe49ca40e09b646d66
https://escholarship.org/uc/item/2fn4f906
https://escholarship.org/uc/item/2fn4f906
Publikováno v:
Biochimica et biophysica acta. Gene regulatory mechanisms. 1860(11)
FMR1 premutation carriers (55-200 CGG repeats) are at risk for developing Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), an adult onset neurodegenerative disorder. Approximately 20% of female carriers will develop Fragile X-associated Primary O